For instance, IGF-IR was expressed in 30% and 25% of patients with chronic phase and accelerated phase CML, respectively, but the expression rate increased to 73% in patients with blast phase CML. This evidence concerns the gene IGF1R and chronic myelogenous leukemia, BCR-ABL1 positive.